I think you are wrong on two fronts.
Firstly, "that approval will likely require the adult trial" - that's not true. So you are wrong here!
Plan A is to discuss the new potency assay data with the FDA this month and that may be sufficient for the Ryoncil BLA Resubmission - i.e. possible approval of Ryoncil for Pediatric without being contingent on the adult trial.
If plan A is successful, then the adult trial has no impact on the approval of Ryoncil for Pediatric.
Secondly, if Plan A fails - then Plan B is activated.
With plan B, there is a need to get the adult trial started, yes started and not completed (as you constantly & wrongly repeat), to get an AA for Ryoncil for Pediatric.
This will require a surrogate end-point - what that is will need to be clarified by the FDA. This surrogate end-point does not need to wait for the adult trial to be completed. AA for Ryoncil for Pediatric will only be requested if and only if, plan A fails.
I think you are wrong on two fronts.Firstly, "that approval will...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.005(0.45%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.15 | $1.11 | $5.667M | 5.064M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 94111 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 70945 | 3 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.12 |
Change
-0.005 ( 1.73 %) |
||||
| Open | High | Low | Volume | ||
| $1.11 | $1.15 | $1.11 | 871975 | ||
| Last updated 15.59pm 03/06/2024 ? | |||||
| MSB (ASX) Chart |